SCHEMBL30457507

SCHEMBL30457507

Cc1nc(N[C@H]2CCN(C(=O)Cc3ccc(F)cc3)C2)ccc1B(O)O

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 6/20 0.68
▸ KCNH2 Q12809 3/20 0.65
▸ ALDH1A1 P00352 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MLNR O43193 4/20 0.47
▸ CYP3A4 P08684 4/20 0.47
▸ LMNA P02545 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ PKM P14618 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ GFER P55789 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ OPRM1 P35372 1/20 0.39
▸ ME2 P23368 1/20 0.39
▸ ME1 P48163 1/20 0.39
▸ ME3 Q16798 1/20 0.39
▸ SYK P43405 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30457448 0.88 MC4R (0.70) MC4RKCNH2ALDH1A1SMN1; SMN2MLNR
SCHEMBL25272696 0.88 MC4R (0.70) MC4RKCNH2ALDH1A1SMN1; SMN2MLNR
SCHEMBL31666902 0.82 MC4R (0.72) MC4RKCNH2ALDH1A1SMN1; SMN2MLNR
SCHEMBL25228967 0.82 MC4R (0.60) MC4RKCNH2ALDH1A1SMN1; SMN2MLNR
SCHEMBL31666906 0.79 MC4R (0.72) MC4RKCNH2ALDH1A1SMN1; SMN2MLNR
SCHEMBL25225367 0.76 ALDH1A1 (0.57) MC4RKCNH2ALDH1A1SMN1; SMN2MLNR
SCHEMBL31666899 0.76 MC4R (0.65) MC4RKCNH2ALDH1A1SMN1; SMN2MLNR
SCHEMBL25277642 0.75 USP30 (0.47) ALDH1A1NPC1RAB9ASYK
SCHEMBL12248697 0.71 SYK (0.51) MC4RKCNH2ALDH1A1SYK
SCHEMBL31666891 0.71 MC4R (0.59) MC4RKCNH2MLNRSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4444708-B1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER (US) 2025-07-30 — — EP disclosed
US-20250129048-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2025-04-24 — — US disclosed
EP-4444708-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF Pfizer Inc. (US) 2024-10-16 — — EP disclosed
CN-118369317-A Melanocortin 4 receptor antagonists and uses thereof 辉瑞大药厂 2024-07-19 — — CN disclosed
WO-2023105387-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2023-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129048-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF MC4R, MC3R, MC2R MC4R 1/4885KCNH2 3260/4885ALDH1A1 3955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback